1.Relationship between immune regulation and structure of polysaccharides.
Nuo CHEN ; Wen-Jie XI ; Mei-Fen HU ; Xing-Ye WEI ; Ping XIAO ; Jin-Ao DUAN
China Journal of Chinese Materia Medica 2023;48(10):2667-2678
		                        		
		                        			
		                        			Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields. At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources. The immune activity of polysaccharides is closely related to their own structure. This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
		                        		
		                        		
		                        		
		                        			Monosaccharides/chemistry*
		                        			;
		                        		
		                        			Structure-Activity Relationship
		                        			;
		                        		
		                        			Molecular Weight
		                        			;
		                        		
		                        			Antioxidants/pharmacology*
		                        			;
		                        		
		                        			Polysaccharides/chemistry*
		                        			
		                        		
		                        	
2.Clinical analysis of 31 cases of fetal umbilical artery thrombosis.
Ruo An JIANG ; Ting XU ; Wen LI ; Ling Fei JIN ; Yi Min ZHOU ; Xiao Xia BAI ; Jing HE
Chinese Journal of Obstetrics and Gynecology 2023;58(7):495-500
		                        		
		                        			
		                        			Objective: To analyze the ultrasonic manifestations, clinical features, high risk factors and key points of pregnancy management in prenatal diagnosis of umbilical artery thrombosis (UAT). Methods: The data of 31 pregnant women of UAT diagnosed by prenatal ultrasonography and confirmed after birth from July 2017 to July 2022 at the Women's Hospital, Zhejiang University School of Medicine were retrospectively analyzed, including the maternal characteristics, pregnancy outcomes and fetal complications. In addition, the baseline data and pregnancy outcomes were compared in 21 patients who continued pregnancy after diagnosis of UAT. Of the 21 UAT cases that continued pregnancy, 10 cases were treated with low molecular weight heparin (LMWH; LMWH treatment group), while the other 11 patients had expectant treatment(expectant treatment group). Results: The age of the 31 pregnant women was (30.2±4.7) years, of which 5 cases (16%,5/31) were advanced age pregnant women. The gestational age at diagnosis was (32.9±4.0) weeks, and the gestational age at termination of pregnancy was (35.6±2.9) weeks. In 31 fetuses with UAT, 15 cases (48%) had fetal distress, 11 cases (35%) had fetal growth restriction, and 3 cases (10%) had intrauterine stillbirth. There were 28 cases of live births, including 26 cases by cesarean section and 2 cases by vaginal delivery. There were also 3 stillbirths, all delivered vaginally. Four neonates had mild asphyxia and two newborns had severe asphyxia. Among the 31 cases, 10 cases were terminated immediately after diagnosis, the gestational age at diagnosis was (35.9±2.9) weeks. Another 21 pregnancies continued, and their gestational age at diagnosis was (31.4±3.7) weeks. The median prolonged gestational age in LMWH treatment group was 7.9 weeks (4.6-9.4 weeks), and all were live births. The median prolonged gestational age in the expectant treatment group was 0.6 weeks (0.0-1.0 weeks), and 2 cases were stillbirths. There was a statistically significant difference in prolonged gestational age (P=0.002). Conclusions: Ultrasound is the preferred method for prenatal detection of UAT. Clinicians need to be vigilant for UAT when a newly identified single umbilical artery is detected by ultrasound in the second or third trimesters. The decision to continue or terminate the pregnancy depends on the gestational age and the condition of fetus. Attention should be paid to fetal movements as the pregnancy continues. The treatment of LMWH as soon as possible after diagnosis of UAT may improve the pregnancy outcome.
		                        		
		                        		
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Infant, Newborn
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Infant
		                        			;
		                        		
		                        			Stillbirth
		                        			;
		                        		
		                        			Cesarean Section
		                        			;
		                        		
		                        			Umbilical Arteries/diagnostic imaging*
		                        			;
		                        		
		                        			Asphyxia
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Heparin, Low-Molecular-Weight/therapeutic use*
		                        			;
		                        		
		                        			Pregnancy Outcome
		                        			;
		                        		
		                        			Fetal Growth Retardation/therapy*
		                        			;
		                        		
		                        			Ultrasonography, Prenatal/methods*
		                        			;
		                        		
		                        			Gestational Age
		                        			
		                        		
		                        	
3.Rapid flavonoid-focused sub-chemome characterization of Draconis Sanguis using UPLC-Q-TOF-MS in combination with molecular weight imprinting and mass defect filtering.
Yi-Jia ZHAO ; Jun LI ; Qing-Qing SONG ; Peng-Fei TU
China Journal of Chinese Materia Medica 2023;48(4):993-1004
		                        		
		                        			
		                        			Draconis Sanguis is a precious Chinese medicinal material for activating blood and resolving stasis, and its effective components are flavonoids. However, the structural diversity of flavonoids in Draconis Sanguis brings great challenges to the in-depth chara-cterization of its chemical composition profiles. To clarify the substance basis of Draconis Sanguis, ultra-high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry(UPLC-Q-TOF-MS) was used in this study to acquire MS data of Draconis Sanguis. The molecular weight imprinting(MWI) and mass defect filtering(MDF) were developed for rapid screening of flavonoids in Draconis Sanguis. Full-scan MS and MS~2 were recorded within the mass range m/z 100-1 000 in positive ion mode. Accor-ding to previous literature, MWI was employed to hunt for reported flavonoids in Draconis Sanguis, and the mass tolerance range of [M+H]~+ was set as ±10×10~(-3). A five-point MDF screening frame was further constructed to narrow the screening range of flavonoids from Draconis Sanguis. Combined with diagnostic fragment ions(DFI) and neutral loss(NL) as well as mass fragmentation pathways, 70 compounds were preliminarily identified from the extract of Draconis Sanguis, including 5 flavan oxidized congeners, 12 flavans, 1 dihydrochalcones, 49 flavonoids dimers, 1 flavonoids trimer and 2 flavonoid derivatives. This study clarified the chemical composition of flavonoids in Draconis Sanguis. Moreover, it also showed that high-resolution MS combined with data post-processing methods such as MWI and MDF could achieve rapid characterization of the chemical composition in Chinese medicinal materials.
		                        		
		                        		
		                        		
		                        			Chromatography, High Pressure Liquid
		                        			;
		                        		
		                        			Flavonoids
		                        			;
		                        		
		                        			Immune Tolerance
		                        			;
		                        		
		                        			Molecular Weight
		                        			;
		                        		
		                        			Plant Extracts/chemistry*
		                        			
		                        		
		                        	
4.Chemical characterization of a new sulfated polysaccharide from Gracilaria chouae and its activation effects on RAW264.7 macrophages.
Feifei LI ; Kehai LIU ; Kewu LIU
Journal of Zhejiang University. Science. B 2022;23(1):84-88
		                        		
		                        			
		                        			This study aimed to characterize the chemical composition of a new sulfated polysaccharide from the red alga Gracilaria chouae and evaluate its activation effects on RAW264.7 macrophages. It showed that the obtained G. chouae polysaccharide (GCP-3A) was a sulfated acidic polysaccharide with a molecular weight of 11.87 kDa. GCP-3A was composed of xylose, galactose, glucose, and mannose with a molar ratio of 3.00:29.28:0.63:0.45, and it contained α,β-glycosidic linkages. Scanning electron microscopy (SEM) and a Congo red test showed that it was a heterogeneous polysaccharide with irregular interwoven sheets and rods, and did not have a triple-helix conformation. Furthermore, GCP-3A significantly promoted the proliferation of RAW264.7 macrophages and the secretion of nitric oxide (NO) in tests of 3-(4,5-dimethylthiahiazo-2-yl)-2,5-diphenytetrazoliumromide(MTT) and NO.
		                        		
		                        		
		                        		
		                        			Gracilaria/chemistry*
		                        			;
		                        		
		                        			Macrophages
		                        			;
		                        		
		                        			Molecular Weight
		                        			;
		                        		
		                        			Polysaccharides/pharmacology*
		                        			;
		                        		
		                        			Sulfates/pharmacology*
		                        			
		                        		
		                        	
5.Prevention of Deep Vein Thrombosis by Panax Notoginseng Saponins Combined with Low-Molecular-Weight Heparin in Surgical Patients.
Chun-Mei WANG ; Xiang-Feng GUO ; Li-Min LIU ; Ying HUANG ; Liang MENG ; Li-Po SONG ; Ying-Feng WU ; Ya-Chan NING ; Kathleen H REILLY ; Hai-Bo WANG
Chinese journal of integrative medicine 2022;28(9):771-778
		                        		
		                        			OBJECTIVE:
		                        			To evaluate the efficacy of deep vein thrombosis (DVT) prevention among real-world surgical inpatients who received panax notoginseng saponins (PNS) combined with low-molecular-weight heparin (LMWH).
		                        		
		                        			METHODS:
		                        			A prospective cohort study was conducted among surgical patients between January 2016 and November 2018 in Xuanwu Hospital, Capital Medical University, Beijing, China. Participants received LMWH alone or PNS combined with LMWH for preventing DVT. The primary outcome was incidence of lower extremity DVT, which was screened once a week. Participants in the LMWH group were given LMWH (enoxaparin) via hypodermic injection, 4000-8000 AxalU once daily. Participants in the exposure group received PNS (Xuesaitong oral tablets, 100 mg, 3 times daily) combined with LMWH given the same as LMWH group.
		                        		
		                        			RESULTS:
		                        			Of the 325 patients screened for the study, 281 participants were included in the final analysis. The cohort was divided into PNS + LMWH group and LMWH group with 134 and 147 participants, respectively. There was a significant difference of DVT incidence between two groups (P=0.01), with 21 (15.7%) incident DVT in the PNS + LMWH group, and 41 (27.9%) incident DVT in the LMWH group. Compared with participants without DVT, the participants diagnosed with DVT were older and had higher D-dimer level. The multivariate logistic regression model showed a significant lower risk of incident DVT among participants in the PNS + LMWH group compared with the LMWH group (odds ratio 0.46, 95% confidence interval, 0.25-0.86). There were no significant differences in thromboelaslography values (including R, K, Angle, and MA) and differences in severe bleeding between two groups. No symptomatic pulmonary embolism occurred during the study.
		                        		
		                        			CONCLUSION
		                        			Combined application of PNS and LMWH can effectively reduce the incidence of DVT among surgical inpatients compared with LMWH monotherapy, without increased risk of bleeding.
		                        		
		                        		
		                        		
		                        			Anticoagulants/therapeutic use*
		                        			;
		                        		
		                        			Hemorrhage
		                        			;
		                        		
		                        			Heparin, Low-Molecular-Weight/therapeutic use*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Panax notoginseng
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Saponins/therapeutic use*
		                        			;
		                        		
		                        			Venous Thrombosis/prevention & control*
		                        			
		                        		
		                        	
6.Low molecular weight heparin reduces arterial blood lactic acid content and increases estimated glomerular filtration rate in patients with moderate Covid-19 pneumonia.
Li MA ; Yigang ZENG ; Bing ZHAO ; Lili XU ; Jian LI ; Tongyu ZHU ; Enqiang MAO
Chinese Medical Journal 2022;135(6):691-696
		                        		
		                        			BACKGROUND:
		                        			Coronavirus disease 2019 (Covid-19) remains a serious health threat worldwide. We aimed to investigate whether low molecular weight heparin (LMWH) can promote organ function recovery in moderate Covid-19 pneumonia patients.
		                        		
		                        			METHODS:
		                        			We initiated an LMWH protocol in Covid-19 patients with increased D-dimer, body mass index >30 kg/m2 or a history of diabetes from January 18, 2020 at Shanghai Public Health Clinical Center. In this retrospective study, we assigned moderate Covid- 19 pneumonia patients admitted between January 18th and April 18, 2020 receiving the LMWH protocol to the LMWH group. Moderate patients who met the inclusion criteria but did not receive LMWH protocol were included in the control group by 1:2 propensity score matching. General clinical information, indicators for renal function, arterial blood gas analyses, arterial blood lactic acid content (mmol/L), and coagulation indexes at 0 day, 3 days, 7 days, and 11 days after admission were recorded and compared between the two groups.
		                        		
		                        			RESULTS:
		                        			There were 41 patients in the LMWH group and 82 patients in the control group. General information in both groups were similar. Compared to the control group, the arterial blood lactic acid content (mmol/L) at day 11 (1.3 [1.1, 1.7] vs. 1.2 [0.9, 1.3], P = 0.016) was reduced in the LMWH group. The estimated glomerular filtration rate (eGFR) in the LMWH group was higher than that in the control group at day 7 (108.54 [89.11, 128.17] vs. 116.85 [103.39, 133.47], P = 0.039) and day 11 (113.74 [94.49, 126.34] vs. 128.31 [112.75, 144, 12], P  = 0.003). The serum creatinine levels (Scr) in the LMWH group were lower than that in the control group at day 7 (62.13 [51.47, 77.64] vs. 55.49 [49.50, 65.75], P = 0.038) and day 11 (63.35 [50.17, 75.73] vs. 51.62 [44.62, 61.24], P = 0.005).
		                        		
		                        			CONCLUSIONS:
		                        			LMWH treatment can reduce arterial blood lactic acid levels and improve eGFR in moderate Covid-19 pneumonia patients. Randomized controlled trials are warranted to further investigate this issue.
		                        		
		                        			TRIAL REGISTRATION
		                        			ChiCTR.org.cn, ChiCTR2000034796.
		                        		
		                        		
		                        		
		                        			COVID-19
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Glomerular Filtration Rate
		                        			;
		                        		
		                        			Heparin, Low-Molecular-Weight/therapeutic use*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lactic Acid
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
7.Advances in the preparation of alginate oligosaccharides and its biological functions.
Chinese Journal of Biotechnology 2022;38(1):104-118
		                        		
		                        			
		                        			Alginate is a group of polyuronic saccharides that are widely used in pharmaceutical and food industry due to its unique physicochemical properties and beneficial health effects. However, the low water solubility and high viscosity of alginate hampered its application. Alginate oligosaccharide (AOS) is a decomposition product of alginate and has received increasing attention due to its low molecular weight, high water solubility, safety, and non-toxicity. The wide-ranging biological functions of AOS are closely related to its structural diversity. AOS with distinct structures and biological functions can be obtained by different methods of preparation. This review summarized the biological functions of AOS reported to date, including anti-tumor, immunomodulatory, anti-inflammatory, antioxidant, prebiotic, and anti-diabetes. The preparation of AOS, as well as the relationship between the structure and biological functions of AOS were discussed, with the aim to provide a reference for further development and application of AOS.
		                        		
		                        		
		                        		
		                        			Alginates
		                        			;
		                        		
		                        			Anti-Inflammatory Agents
		                        			;
		                        		
		                        			Antioxidants
		                        			;
		                        		
		                        			Molecular Weight
		                        			;
		                        		
		                        			Oligosaccharides
		                        			
		                        		
		                        	
8.The Treatment Options and Clinical Significance of Immune Thrombocytopenia Patients with Splanchnic Vein Thrombosis as the Initial Manifestation.
Lin LIN ; Ran YANG ; Yu WU ; Hui HUANG ; Ou JI ; Qun SHEN
Journal of Experimental Hematology 2021;29(3):887-892
		                        		
		                        			OBJECTIVE:
		                        			To investigate the causes, treatment options and outcomes of immune thrombocytopenia (ITP) patients with splanchnic venous thrombosis (SVT).
		                        		
		                        			METHODS:
		                        			The clinical diagnosis, treatment and outcomes data of one 26-year-old male ITP patient with SVT as initial manifestation were collected. The possible causes and treatment options of the patients were discussed through literatures review.
		                        		
		                        			RESULTS:
		                        			The result of blood routine tests of the patient showed that Plt(17-38)×10
		                        		
		                        			CONCLUSION
		                        			ITP combined with large scale of SVT is rare, and it is difficult to cure. It should be pay more attention to the possible thrombosis risk triggered by a transiently increased EOS in the blood stream. Promptly etiological treatment and the balance between anticoagulant therapy and bleeding risks should be taken in clinical practice.
		                        		
		                        		
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Anticoagulants/therapeutic use*
		                        			;
		                        		
		                        			Heparin, Low-Molecular-Weight
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Purpura, Thrombocytopenic, Idiopathic/complications*
		                        			;
		                        		
		                        			Splanchnic Circulation
		                        			;
		                        		
		                        			Venous Thrombosis
		                        			
		                        		
		                        	
9.Therapeutic Effect of Spleen Low Molecular Weight Extracts on Leukopenia Caused by Epirubicin in Mice and Its Mechanism.
Yi-Ting LIN ; Xin-Yue ZHENG ; Yi-Fan YAO ; Yu-Ying ZHANG ; Ting-Ting HUANG ; Yun-Lan ZHU ; Jun PEI ; Jin WANG ; Ming CHU ; Yue-Dan WANG
Journal of Experimental Hematology 2021;29(3):969-974
		                        		
		                        			OBJECTIVE:
		                        			To investigate the therapeutic effect of spleen low molecular weight extracts on epileptics hydrochloride-induced leukopenia in mice and explore its mechanism.
		                        		
		                        			METHODS:
		                        			The model of leukopenia in mice was established by the injection of epirubicin hydrochloride (10 mg/kg). After the injection of chemotherapeutic drugs, leukocytopenia mice were treated with different doses of spleen low molecular weight extract, Ganoderma oral solution and recombinant granulocyte colony stimulating factor (rhG-CSF). The general survival status indicators such as body weight, coat color and athletic ability of mice in each group were recorded; the tail vein blood of mice in each group was collected and the white blood cell count in them was calculated; bone marrow of mice was taken and bone marrow smears were observed.
		                        		
		                        			RESULTS:
		                        			In the model group, the weight of the mice gradually decreased in the later period, their coat became dark and rough, and the ability to exercise decreased, while the mice in the treatment groups showed different degrees of improvement in their survival status except for the mice treated by rhG-CSF. There was no significant fluctuation in the white blood cell count of the blank control mice. After injection of epirubicin, the white blood cell count of peripheral blood in the model mice and treated mice were decreased. The white blood cell count was lower in the mice treated with high-dose low molecular weight extract and rhG-CSF than that in other experimental groups. Bone marrow smear showed that the proportion of bone marrow nucleated cells in the mice treated with the low molecular weight extract of the spleen was significantly higher than that of model mice (P<0.05).
		                        		
		                        			CONCLUSION
		                        			The low molecular weight spleen extracts can significantly improve the hematopoietic state of mouse bone marrow, promote the proliferation of inhibited bone marrow cells, and thus has the effect of treating leukopenia in mice.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Epirubicin
		                        			;
		                        		
		                        			Granulocyte Colony-Stimulating Factor
		                        			;
		                        		
		                        			Leukocyte Count
		                        			;
		                        		
		                        			Leukopenia/drug therapy*
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Molecular Weight
		                        			;
		                        		
		                        			Plant Extracts
		                        			;
		                        		
		                        			Recombinant Proteins
		                        			;
		                        		
		                        			Spleen
		                        			
		                        		
		                        	
10.Mechanical heart valve thrombosis during pregnancy under non
Journal of Central South University(Medical Sciences) 2021;46(2):207-211
		                        		
		                        			
		                        			Anticoagulation drugs should be used for patients with mechanical heart valve (MHV) in case of potential risk of thrombosis. Pregnant women with MHV have to change therapies due to teratogenic effect of some anti-coagulation drugs. European Society of Cardiology clinical guidelines for the management of cardiovascular diseases during pregnancy gives specific suggestions for anticoagulation therapy.We have treated 2 patients with mechanical heart valve thrombosis (MVT) during pregnancy: One received low molecular weight heparin (LMWH) throughout the pregnancy and developed MVT at the third trimester of pregnancy; one developed MVT at the first trimester when replacing vitamin K antagonists (VKA) with LMWH. These patients raised secondary reflection on the balance between clinical guideline and personalized medicine. During LMWH therapy, we should dynamically monitor patients' anti-activated factor X (anti-Xa) level to evaluate coagulation function during pregnancy. When a pregnant woman with MHV develops symptoms of acute heart failure, stuck mechanical valve should be paid attention to and surgery should be promptly performed if necessary.
		                        		
		                        		
		                        		
		                        			Anticoagulants/adverse effects*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Heart Valve Prosthesis/adverse effects*
		                        			;
		                        		
		                        			Heart Valves
		                        			;
		                        		
		                        			Heparin, Low-Molecular-Weight/adverse effects*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Pregnancy Complications, Cardiovascular/drug therapy*
		                        			;
		                        		
		                        			Thrombosis/drug therapy*
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail